FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1966725589> ?p ?o ?g. }

• W1966725589 endingPage "1314" @default.
• W1966725589 startingPage "1310" @default.
• W1966725589 abstract "Objectives To analyze results of intensity-modulated radiotherapy after cryotherapy ablation for adenocarcinoma of the prostate. Methods Patients were either treated adjuvantly after targeted cryotherapy or treated for salvage after local failure of standard whole-prostate cryotherapy. Patients were treated with intensity-modulated radiotherapy to a minimum dose of 73 Gy (mean dose, >75Gy). Prostate-specific antigen (PSA) failure was defined according to the Radiation Therapy Oncology Group–American Society for Therapeutic Radiology and Oncology 2006 consensus definition. Late gastrointestinal and genitourinary toxicity were graded according to the Radiation Therapy Oncology Group late toxicity scale and the Late Effects of Normal Tissue–Subjective, Objective, Management, and Analytic scale. Results A total of 16 patients were treated from 1997 to 2007. Three patients were treated adjuvantly, and 13 patients were treated for local failure. The mean pre-cryotherapy PSA value was 8.7 ng/mL. The mean PSA value before irradiation was 6.0 ng/mL. Most patients were intermediate to high risk (8 intermediate risk, 7 high risk). Median follow-up was 33 months. No grade 3 or greater toxicity was seen. Biochemical (PSA) control was achieved in 12 of the 16 patients at last follow-up. Conclusions Full-dose intensity-modulated radiotherapy after cryotherapy is well tolerated, without excess late morbidity. This study supports the use of radiation for cryotherapy failure salvage. Furthermore, the combination of cryotherapy and irradiation may be considered in a phase II trial. To analyze results of intensity-modulated radiotherapy after cryotherapy ablation for adenocarcinoma of the prostate. Patients were either treated adjuvantly after targeted cryotherapy or treated for salvage after local failure of standard whole-prostate cryotherapy. Patients were treated with intensity-modulated radiotherapy to a minimum dose of 73 Gy (mean dose, >75Gy). Prostate-specific antigen (PSA) failure was defined according to the Radiation Therapy Oncology Group–American Society for Therapeutic Radiology and Oncology 2006 consensus definition. Late gastrointestinal and genitourinary toxicity were graded according to the Radiation Therapy Oncology Group late toxicity scale and the Late Effects of Normal Tissue–Subjective, Objective, Management, and Analytic scale. A total of 16 patients were treated from 1997 to 2007. Three patients were treated adjuvantly, and 13 patients were treated for local failure. The mean pre-cryotherapy PSA value was 8.7 ng/mL. The mean PSA value before irradiation was 6.0 ng/mL. Most patients were intermediate to high risk (8 intermediate risk, 7 high risk). Median follow-up was 33 months. No grade 3 or greater toxicity was seen. Biochemical (PSA) control was achieved in 12 of the 16 patients at last follow-up. Full-dose intensity-modulated radiotherapy after cryotherapy is well tolerated, without excess late morbidity. This study supports the use of radiation for cryotherapy failure salvage. Furthermore, the combination of cryotherapy and irradiation may be considered in a phase II trial." @default.
• W1966725589 created "2016-06-24" @default.
• W1966725589 creator A5006150857 @default.
• W1966725589 creator A5036605151 @default.
• W1966725589 creator A5040475138 @default.
• W1966725589 creator A5050392689 @default.
• W1966725589 creator A5074737662 @default.
• W1966725589 date "2008-12-01" @default.
• W1966725589 modified "2023-09-23" @default.
• W1966725589 title "Intensity-Modulated Radiotherapy of the Prostate After Cryotherapy: Initial Experience" @default.
• W1966725589 cites W1868732334 @default.
• W1966725589 cites W1990686188 @default.
• W1966725589 cites W1996809772 @default.
• W1966725589 cites W2001359971 @default.
• W1966725589 cites W2016557692 @default.
• W1966725589 cites W2039960040 @default.
• W1966725589 cites W2047122497 @default.
• W1966725589 cites W2063757374 @default.
• W1966725589 cites W2068056634 @default.
• W1966725589 cites W2074866106 @default.
• W1966725589 cites W2080046326 @default.
• W1966725589 cites W2093037227 @default.
• W1966725589 cites W2093867637 @default.
• W1966725589 cites W2129054091 @default.
• W1966725589 cites W2137900501 @default.
• W1966725589 cites W2138987578 @default.
• W1966725589 cites W2153674426 @default.
• W1966725589 cites W2160537008 @default.
• W1966725589 cites W2163954169 @default.
• W1966725589 doi "https://doi.org/10.1016/j.urology.2008.01.079" @default.
• W1966725589 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18502482" @default.
• W1966725589 hasPublicationYear "2008" @default.
• W1966725589 type Work @default.
• W1966725589 sameAs 1966725589 @default.
• W1966725589 citedByCount "11" @default.
• W1966725589 countsByYear W19667255892013 @default.
• W1966725589 countsByYear W19667255892016 @default.
• W1966725589 countsByYear W19667255892018 @default.
• W1966725589 countsByYear W19667255892019 @default.
• W1966725589 countsByYear W19667255892021 @default.
• W1966725589 countsByYear W19667255892023 @default.
• W1966725589 crossrefType "journal-article" @default.
• W1966725589 hasAuthorship W1966725589A5006150857 @default.
• W1966725589 hasAuthorship W1966725589A5036605151 @default.
• W1966725589 hasAuthorship W1966725589A5040475138 @default.
• W1966725589 hasAuthorship W1966725589A5050392689 @default.
• W1966725589 hasAuthorship W1966725589A5074737662 @default.
• W1966725589 hasConcept C121608353 @default.
• W1966725589 hasConcept C126322002 @default.
• W1966725589 hasConcept C126894567 @default.
• W1966725589 hasConcept C133507102 @default.
• W1966725589 hasConcept C141071460 @default.
• W1966725589 hasConcept C143998085 @default.
• W1966725589 hasConcept C2776235491 @default.
• W1966725589 hasConcept C2776694085 @default.
• W1966725589 hasConcept C2778902805 @default.
• W1966725589 hasConcept C2780149145 @default.
• W1966725589 hasConcept C2780192828 @default.
• W1966725589 hasConcept C2780775027 @default.
• W1966725589 hasConcept C509974204 @default.
• W1966725589 hasConcept C71924100 @default.
• W1966725589 hasConceptScore W1966725589C121608353 @default.
• W1966725589 hasConceptScore W1966725589C126322002 @default.
• W1966725589 hasConceptScore W1966725589C126894567 @default.
• W1966725589 hasConceptScore W1966725589C133507102 @default.
• W1966725589 hasConceptScore W1966725589C141071460 @default.
• W1966725589 hasConceptScore W1966725589C143998085 @default.
• W1966725589 hasConceptScore W1966725589C2776235491 @default.
• W1966725589 hasConceptScore W1966725589C2776694085 @default.
• W1966725589 hasConceptScore W1966725589C2778902805 @default.
• W1966725589 hasConceptScore W1966725589C2780149145 @default.
• W1966725589 hasConceptScore W1966725589C2780192828 @default.
• W1966725589 hasConceptScore W1966725589C2780775027 @default.
• W1966725589 hasConceptScore W1966725589C509974204 @default.
• W1966725589 hasConceptScore W1966725589C71924100 @default.
• W1966725589 hasIssue "6" @default.
• W1966725589 hasLocation W19667255891 @default.
• W1966725589 hasLocation W19667255892 @default.
• W1966725589 hasOpenAccess W1966725589 @default.
• W1966725589 hasPrimaryLocation W19667255891 @default.
• W1966725589 hasRelatedWork W1497406605 @default.
• W1966725589 hasRelatedWork W1980188241 @default.
• W1966725589 hasRelatedWork W1993064858 @default.
• W1966725589 hasRelatedWork W2022571942 @default.
• W1966725589 hasRelatedWork W2127440557 @default.
• W1966725589 hasRelatedWork W2590008096 @default.
• W1966725589 hasRelatedWork W2766396754 @default.
• W1966725589 hasRelatedWork W2897445903 @default.
• W1966725589 hasRelatedWork W3082324229 @default.
• W1966725589 hasRelatedWork W9173564 @default.
• W1966725589 hasVolume "72" @default.
• W1966725589 isParatext "false" @default.
• W1966725589 isRetracted "false" @default.
• W1966725589 magId "1966725589" @default.
• W1966725589 workType "article" @default.